2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Sunday, October 21, 2018

9:00AM-11:00AM: Abstract Number: 738

Two Clinical Phenotypes of Chinese SLE-PAH Patients

Systemic Lupus Erythematosus – Clinical Poster I: Clinical Manifestations and Comorbidity

9:00AM-11:00AM: Abstract Number: 538

Type 1 Diabetes in RA: Comparison with Type 2 and Its Association with RA Severity and Treatment

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster I: Comorbidities

9:00AM-11:00AM: Abstract Number: 91

Type I IFN Production Is Induced By Non-Haematopoietic Tissue Cells but Not Plasmacytoid Dendritic Cells in Preclinical Autoimmunity and SLE

Systemic Lupus Erythematosus – Etiology and Pathogenesis Poster I

9:00AM-11:00AM: Abstract Number: 561

U-Act-Early Trial 3 Years Follow-up: Radiographic Joint Damage and Use of Bdmards over 5 Years in Early RA Patients Treated-to-Target with Strategies Initiating Tocilizumab, Methotrexate or Their Combination

Rheumatoid Arthritis – Treatments Poster I: Strategy and Epidemiology

9:00AM-11:00AM: Abstract Number: 225

U.S. Trends in Hospitalization Rates and Causes and in-Hospital Mortality in Rheumatoid Arthritis Patients, 2000-2014

Epidemiology and Public Health Poster I: Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 678

Ultrasonographic Evaluation of Achilles Tendon in Early Axial Spondyloarthropathy: Is There Any Difference between Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthropathy?

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Imaging, Clinical Studies, and Treatment

9:00AM-11:00AM: Abstract Number: 679

Ultrasonographic Research of the Relationship between Nail Disorders and Peripheral Arthritis or Enthesitis in Patients with Psoriasis and Psoriatic Arthritis

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Imaging, Clinical Studies, and Treatment

9:00AM-11:00AM: Abstract Number: 109

Unique miRNA Signatures Detected in Extracellular Vesicles from Patients with Systemic Lupus Erythematous

Systemic Lupus Erythematosus – Etiology and Pathogenesis Poster I

9:00AM-11:00AM: Abstract Number: 409

Unique Skeletal Muscle Relaxant Tolperisone in a Crossover Driving Simulation Study: No Evidence of Sedation Compared to Cyclobenzaprine and Placebo

Orthopedics, Low Back Pain and Rehabilitation Poster – ACR/ARHP

9:00AM-11:00AM: Abstract Number: 571

United States Rheumatology Practice-Based Real-World Evidence of Methotrexate Utilization and Response to Therapy in Rheumatoid Arthritis Patients Treated with Intravenous Golimumab

Rheumatoid Arthritis – Treatments Poster I: Strategy and Epidemiology

9:00AM-11:00AM: Abstract Number: 680

Unmet Needs in the Treatment of Ankylosing Spondylitis. a Long-Term Observational Study from a Single University Center

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Imaging, Clinical Studies, and Treatment

9:00AM-11:00AM: Abstract Number: 549

Unmet Treat-to-Target Goals with Available Targeted Immunomodulators in the Management of Rheumatoid Arthritis: Real World Evidence from the Corrona Registry

Rheumatoid Arthritis – Treatments Poster I: Strategy and Epidemiology

9:00AM-11:00AM: Abstract Number: 757

Urinary Galectin-3 Binding Protein As a Novel Biomarker of Renal Disease Activity in Lupus Nephritis

Systemic Lupus Erythematosus – Clinical Poster I: Clinical Manifestations and Comorbidity

9:00AM-11:00AM: Abstract Number: 739

Urine and Plasma Soluble Triggering Receptor Expressed on Myeloid Cells-1 (sTREM-1) Differentially Correlates with Renal and Non-Renal Systemic Lupus Erythematosus (SLE): A Prospective, Case-Control Study

Systemic Lupus Erythematosus – Clinical Poster I: Clinical Manifestations and Comorbidity

9:00AM-11:00AM: Abstract Number: 780

Urine Metabolomic Profile in Lupus Nephritis

Systemic Lupus Erythematosus – Clinical Poster I: Clinical Manifestations and Comorbidity

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].